Nasus Pharma H1 FY26 net loss widens to $5.94 million
Reuters2026/08/17 12:14- Nasus Pharma posted a net loss of USD 5.9 million for the six months ended June 30, 2026, widening from USD 1.3 million.
- R&D expense rose to USD 2.6 million from USD 0.3 million, driven by spending tied to NS002 development.
- G&A costs climbed to USD 3.4 million from USD 0.5 million, mainly due to expenses of becoming a public company.
- Cash, cash equivalents and short-term deposits increased to USD 11.9 million from USD 4.3 million, following a USD 15 million private placement.
- Nasus named Brendan P. O’Grady CEO; NS002 pivotal study remains slated for Q4 2026, with topline data expected in Q1 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OpenAI executives resigning one after another sparks concerns; the president reassures: It's actually normal, we're just under a lot of attention
OpenAI co-founder and president Greg Brockman said on Monday that OpenAI is "under intense scrutiny, so every departure is examined extremely closely," and that these recent personnel changes "are actually not unusual." In recent weeks, three executives have announced their departures: Denise Dresser, head of revenue; Brad Lightcap, executive officer; and Fidji Simo, head of product and business.
10x Genomics director Sarah A. Teichmann disposes of USD 433,106 in common shares
Rusoro says court dismisses five of Gold Reserve’s six claims in lawsuit
Crypto prices
More
